



Medi-Cal Rx

Pemgarda™ (pemivibart) Now a Medi-Cal Rx Benefit

September 24, 2024

Background

The purpose of this alert is to notify pharmacy providers and prescribers that the U.S. Food and Drug Administration (FDA) issued an [Emergency Use Authorization \(EUA\) for Pemgarda™ \(pemivibart\)](#) for the pre-exposure prophylaxis of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 88 lb. [40 kg]) who are moderately or severely immunocompromised and are unlikely to mount an adequate immune response to the COVID-19 vaccination. Pre-exposure prophylaxis helps prevent COVID-19 but does not take the place of vaccination in people who are eligible to receive an updated COVID-19 vaccine.

What Pharmacy Providers and Prescribers Need to Know

Effective March 28, 2024, Pemgarda (pemivibart) is available to Medi-Cal Rx members as a pharmacy benefit, contingent upon an approved prior authorization (PA) request when medically necessary.

Antibody	Concentration	Package Size	NDC
Pemivibart	500 mg/4 ml vial (125 mg/ml)	4 ml vial	81960003103

Coverage for this product is effective for claims with a date of service (DOS) on and after March 28, 2024. Pharmacy providers may retroactively bill Medi-Cal Rx for this product and also submit retroactive PA requests.

The product can be obtained through Cardinal Health, Cencora, McKesson Plasma and Biologics, or McKesson Specialty Care Distribution. For more information, visit the product ordering guide on the manufacturer's website.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.